trending Market Intelligence /marketintelligence/en/news-insights/trending/a8V51VF5_eyvUHusA2PtaA2 content esgSubNav
In This List

US FDA approves clinical trials of Cerenis drug for liver disease

Blog

Insight Weekly: M&A players predict 2023 activity; SPAC IPOs dip; 2022 capacity retirements up

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share


US FDA approves clinical trials of Cerenis drug for liver disease

The U.S. FDA approved has given the go-ahead for clinical trials of Cerenis Therapeutics Holding SA's CER-209 drug candidate.

The investigational new drug application for CER-209 involves plans for a phase 1 clinical study in healthy volunteers for the clinical investigation of nonalcoholic fatty liver disease and nonalcoholic steato-hepatitis.

Cerenis intends to start enrollment for the clinical study in the first quarter of 2017.